UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Journal of clinical oncology, 2021-08, Vol.39 (24), p.2647-2655

2021

Volltextzugriff (PDF)

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Journal of clinical oncology, 2021-08, Vol.39 (24), p.2656-2666

2021

Volltextzugriff (PDF)

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

Clinical cancer research, 2019-10, Vol.25 (19), p.5961-5971

2019

Volltextzugriff (PDF)

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

The New England journal of medicine, 2018-08, Vol.379 (8), p.722-730

2018

Volltextzugriff (PDF)

Systemic Therapy for Melanoma: ASCO Guideline

Journal of clinical oncology, 2020-11, Vol.38 (33), p.3947-3970

2020

Volltextzugriff (PDF)

Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?

Journal of clinical oncology, 2018-06, Vol.36 (17), p.1649-1653

Khushalani, Nikhil I

2018

Volltextzugriff (PDF)

Principles of Targeted Therapy for Melanoma

The Surgical clinics of North America, 2020-02, Vol.100 (1), p.175-188

2020

Volltextzugriff (PDF)

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000775

2020

Volltextzugriff (PDF)

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

The lancet oncology, 2020-02, Vol.21 (2), p.294-305

2020

Volltextzugriff (PDF)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (11), p.1961-1973

2021

Volltextzugriff (PDF)

Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma

Cancer, 2022-11, Vol.128 (21), p.3764-3771

2022

Volltextzugriff (PDF)

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Clinical cancer research, 2022-05, Vol.28 (10), p.2131-2146

2022

Volltextzugriff (PDF)

Development of Targeted Alpha Particle Therapy for Solid Tumors

Molecules (Basel, Switzerland), 2019-11, Vol.24 (23), p.4314

2019

Volltextzugriff (PDF)

Echoes of a failure: what lessons can we learn?

The lancet oncology, 2019-08, Vol.20 (8), p.1037-1039

2019

Volltextzugriff (PDF)

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

European journal of cancer (1990), 2017-04, Vol.75, p.47-55

2017

Volltextzugriff (PDF)

Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients

Cancer, 2023-06, Vol.129 (11), p.1723-1734

2023

Volltextzugriff (PDF)

Current Immunotherapy Practices in Melanoma

Surgical oncology clinics of North America, 2019-07, Vol.28 (3), p.403-418

2019

Volltextzugriff (PDF)

1 – 25 von 225

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(211)
Mit Volltextzugriff
(190)

Publikationsform

Sprache

Englisch
(224)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Systemic Therapy for Melanoma: ASCO Guideline

Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

Principles of Targeted Therapy for Melanoma

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Development of Targeted Alpha Particle Therapy for Solid Tumors

Echoes of a failure: what lessons can we learn?

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Current Immunotherapy Practices in Melanoma

Suchergebnisse filtern